top of page

DISRUPT Networking Evening Oct. 11, 2022

Updated: Dec 15, 2022

We had a kick-off networking event with the DISRUPT team and guests that included directors from Columbia, Mount Sinai, and Einstein/Montefiore Cancer Centers, as well as City College of New York.





 
 
 

Recent Posts

See All
NCI-2025-06021

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (TRIPL) This is a research study exploring how combining radiation therapy with dual immune check

 
 
 
NCI-2024-05588

A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT) The INSI

 
 
 
NCI-2022-08569

Randomized Phase III Trial of mFOLFIRINOX /- Nivolumab vs. FOLFOX /- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma This randomized Phase III research

 
 
 

Comments

bottom of page